Metagenomi (MGX) Competitors

Candel Therapeutics (NASDAQ:CADL) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, community ranking, profitability, institutional ownership, earnings and valuation.

Do analysts prefer CADL or MGX?

Candel Therapeutics currently has a consensus price target of $21.00, suggesting a potential upside of 180.00%. Metagenomi has a consensus price target of $14.40, suggesting a potential upside of 805.66%. Given Metagenomi's higher probable upside, analysts clearly believe Metagenomi is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Metagenomi	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Do institutionals and insiders believe in CADL or MGX?

13.9% of Candel Therapeutics shares are held by institutional investors. 41.6% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Which has preferable valuation & earnings, CADL or MGX?

Candel Therapeutics has higher earnings, but lower revenue than Metagenomi. Candel Therapeutics is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	$120K	2,952.19	-$37.94M	-$1.75	-4.29
Metagenomi	$52.30M	1.14	-$68.25M	-$2.62	-0.61

Does the media refer more to CADL or MGX?

In the previous week, Candel Therapeutics had 8 more articles in the media than Metagenomi. MarketBeat recorded 10 mentions for Candel Therapeutics and 2 mentions for Metagenomi. Candel Therapeutics' average media sentiment score of 0.45 beat Metagenomi's score of 0.29 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is CADL or MGX more profitable?

Candel Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -134.27%. Metagenomi's return on equity of -43.23% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-629.29%	-173.39%
Metagenomi	-134.27%	-43.23%	-18.86%

Does the MarketBeat Community believe in CADL or MGX?

Metagenomi received 4 more outperform votes than Candel Therapeutics when rated by MarketBeat users. Likewise, 95.24% of users gave Metagenomi an outperform vote while only 66.67% of users gave Candel Therapeutics an outperform vote.

Company	Underperform	Outperform
Candel Therapeutics	Outperform Votes 16 66.67%	Underperform Votes 8 33.33%
Metagenomi	Outperform Votes 20 95.24%	Underperform Votes 1 4.76%

Summary

Candel Therapeutics beats Metagenomi on 9 of the 16 factors compared between the two stocks.